Is the occurrence of higher adverse effects associated with better oncological outcome in metastatic urothelial carcinoma patients treated with pembrolizumab?

被引：0
|
作者：
Hayakawa, Nozomi
Kikuchi, Eiji
Ogihara, Koichirou
Hattori, Seiya
Yoshimine, Shunsuke
Shirotake, Suguru
Okabe, Takashi
Yamashita, Ryo
Oya, Mototsugu
机构：
[1] Keio Univ, Dept Urol, Sch Med, Tokyo, Japan
[2] Kawasaki Municipal Hosp, Kawasaki, Kanagawa, Japan
[3] Saitama City Hosp, Saitama, Japan
[4] Saitama Med Univ, Int Med Ctr, Saitama, Japan
[5] Shizuoka Canc Ctr, Shizuoka, Japan
[6] Keio Univ, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.405
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
405
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab
    Castel-Ajgal, Zahra
    Goulvestre, Claire
    Zaibet, Sonia
    Arrondeau, Jennifer
    Bretagne, Marie
    Peyromaure, Michael
    Batteux, Frederic
    Alexandre, Jerome
    Goldwasser, Francois
    Huillard, Olivier
    CLINICAL GENITOURINARY CANCER, 2022, 20 (05) : E362 - E368
  • [2] Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab
    Sekito, Takanori
    Bekku, Kensuke
    Katayama, Satoshi
    Watanabe, Tomofumi
    Tsuboi, Ichiro
    Yoshinaga, Kasumi
    Maruyama, Yuki
    Yamanoi, Tomoaki
    Kawada, Tatsushi
    Tominaga, Yusuke
    Sadahira, Takuya
    Iwata, Takehiro
    Nishimura, Shingo
    Kusumi, Norihiro
    Edamura, Kohei
    Kobayashi, Tomoko
    Kurose, Kyohei
    Ichikawa, Takaharu
    Miyaji, Yoshiyuki
    Wada, Koichiro
    Kobayashi, Yasuyuki
    Araki, Motoo
    CLINICAL GENITOURINARY CANCER, 2024, 22 (04)
  • [3] ASSOCIATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND SURVIVAL OF PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA TREATED WITH PEMBROLIZUMAB
    Nakamura, Kazutaka
    Toshio, Takagi
    Nemoto, Yuki
    Ishiyama, Yudai
    Ishihara, Hiroki
    Tachibana, Hidekazu
    Fukuda, Hironori
    Shinmura, Hiroaki
    Hashimoto, Yasunobu
    Kondo, Tsunenori
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Ishida, Hideki
    Tanabe, Kazunari
    JOURNAL OF UROLOGY, 2022, 207 (05): : E28 - E28
  • [4] Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab
    Hashimoto, Masaki
    Fukuokaya, Wataru
    Yanagisawa, Takafumi
    Yamamoto, Shutaro
    Koike, Yuhei
    Imai, Yu
    Iwatani, Kosuke
    Onuma, Hajime
    Ito, Kagenori
    Urabe, Fumihiko
    Tsuzuki, Shunsuke
    Kimura, Shoji
    Oyama, Yu
    Abe, Hirokazu
    Miki, Jun
    Kimura, Takahiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (05) : 612 - 619
  • [5] Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab
    Masaki Hashimoto
    Wataru Fukuokaya
    Takafumi Yanagisawa
    Shutaro Yamamoto
    Yuhei Koike
    Yu Imai
    Kosuke Iwatani
    Hajime Onuma
    Kagenori Ito
    Fumihiko Urabe
    Shunsuke Tsuzuki
    Shoji Kimura
    Yu Oyama
    HIrokazu Abe
    Jun Miki
    Takahiro Kimura
    International Journal of Clinical Oncology, 2024, 29 : 612 - 619
  • [6] Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab
    Kunimitsu, Yoko
    Morio, Kayoko
    Hirata, Sachi
    Yamamoto, Kazuhiro
    Omura, Tomohiro
    Hara, Takuto
    Harada, Kenichi
    Fujisawa, Masato
    Yanoa, Ikuko
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2022, 45 (05) : 590 - 595
  • [7] Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab
    Katayama, Satoshi
    Iwata, Takehiro
    Kawada, Tasushi
    Okamoto, Yusuke
    Sano, Yuho
    Kawago, Yuya
    Miyake, Shuji
    Moriwake, Takatoshi
    Kuinose, Aya
    Horikawa, Yuhei
    Tsuboi, Kazuma
    Tsuboi, Ichiro
    Sakaeda, Kazuma
    Nakatsuka, Hirokazu
    Takamoto, Atsushi
    Hirata, Takeshi
    Shirasaki, Yoshinori
    Yamasaki, Taku
    Morinaka, Hirofumi
    Nagasaki, Naoya
    Hara, Takafumi
    Ochi, Akinori
    Okumura, Misa
    Watanabe, Tomofumi
    Sekito, Takanori
    Kawano, Kaoru
    Horii, Satoshi
    Yamanoi, Tomoaki
    Nagao, Kentaro
    Yoshinaga, Kasumi
    Maruyama, Yuki
    Tominaga, Yusuke
    Sadahira, Takuya
    Nishimura, Shingo
    Edamura, Kohei
    Kobayashi, Tomoko
    Kusumi, Norihiro
    Kurose, Kyohei
    Yamamoto, Yasuo
    Sugimoto, Morito
    Nakada, Tetsuya
    Sasaki, Katsumi
    Takenaka, Tadasu
    Ebara, Shin
    Miyaji, Yoshiyuki
    Wada, Koichiro
    Kobayashi, Yasuyuki
    Araki, Motoo
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (03) : 70.e11 - 70.e18
  • [8] Impact of antacids on the prognosis of patients with metastatic urothelial carcinoma treated with pembrolizumab: A retrospective multicenter study
    Sekito, T.
    Katayama, S.
    Iwata, T.
    Kawada, T.
    Tominaga, Y.
    Sadahira, T.
    Nishimura, S.
    Bekku, K.
    Edamura, K.
    Kobayashi, T.
    Kobayashi, Y.
    Araki, M.
    EUROPEAN UROLOGY, 2024, 85 : S1734 - S1735
  • [9] Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
    Inokuchi, Junichi
    Eto, Masatoshi
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4519 - 4528
  • [10] Chronological transition in oncological outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval
    Naiki, T.
    Isobe, T.
    Sugiyama, Y.
    Etani, T.
    Gonda, M.
    Aoki, M.
    Morikawa, T.
    Iwatsuki, S.
    Taguchi, K.
    Hamamoto, S.
    Yasui, T.
    EUROPEAN UROLOGY, 2023, 83 : S766 - S767
12345